Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

NKTR

Nektar Therapeutics

Feb 06 • 04:00PM ET

36.81

+1.69 4.81 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB VRTX GILD REGN INCY IONS SRPT EXEL NBIX

| Held by: VTI VXF SCHA XPH PRFZ VHT IHE LFSC SURI ITOT

Index	-	P/E	-	EPS (ttm)	-7.94	Insider Own	1.46%	Shs Outstand	20.34M	Perf Week	-1.39%
Market Cap	748.78M	Forward P/E	-	EPS next Y	-9.87	Insider Trans	-10.01%	Shs Float	20.04M	Perf Month	-15.40%
Enterprise Value	645.65M	PEG	-	EPS next Q	-2.42	Inst Own	71.88%	Short Float	16.29%	Perf Quarter	-32.16%
Income	-120.74M	P/S	11.96	EPS this Y	-15.44%	Inst Trans	40.07%	Short Ratio	4.15	Perf Half Y	69.24%
Sales	62.60M	P/B	8.50	EPS next Y	1.74%	ROA	-39.63%	Short Interest	3.26M	Perf YTD	-12.94%
Book/sh	4.33	P/C	2.77	EPS next 5Y	-9.84%	ROE	-180.24%	52W High	66.92 -44.99%	Perf Year	222.89%
Cash/sh	13.28	P/FCF	-	EPS past 3/5Y	41.29% 25.49%	ROIC	-52.50%	52W Low	0.43 8420.83%	Perf 3Y	-16.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.15% -3.00%	Gross Margin	85.92%	Volatility	7.29% 6.67%	Perf 5Y	-88.14%
Dividend TTM	-	EV/Sales	10.31	EPS Y/Y TTM	36.87%	Oper. Margin	-217.83%	ATR (14)	2.64	Perf 10Y	-82.01%
Dividend Ex-Date	-	Quick Ratio	4.24	Sales Y/Y TTM	-32.79%	Profit Margin	-192.87%	RSI (14)	42.66	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	4.24	EPS Q/Q	29.43%	SMA20	-0.68%	Beta	-0.87	Target Price	114.43
Payout	-	Debt/Eq	1.96	Sales Q/Q	-51.13%	SMA50	-18.47%	Rel Volume	0.52	Prev Close	35.12
Employees	61	LT Debt/Eq	1.70	Earnings	Nov 06 AMC	SMA200	1.96%	Avg Volume	785.83K	Price	36.81
IPO	May 03, 1994	Option/Short	Yes / Yes	EPS/Sales Surpr.	30.35% 17.26%	Trades		Volume	411,714	Change	4.81%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-26-25	Initiated	Citigroup	Buy	$102
Jun-24-25	Reiterated	H.C. Wainwright	Buy	$6.50 → $120
Jun-24-25	Reiterated	BTIG Research	Buy	$60 → $100
Apr-11-25	Upgrade	Jefferies	Hold → Buy	$2
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform	$6
Jan-08-25	Initiated	B. Riley Securities	Buy	$4
Dec-10-24	Initiated	H.C. Wainwright	Buy	$6.50
Nov-04-24	Initiated	Piper Sandler	Overweight	$7
Sep-30-24	Resumed	BTIG Research	Buy	$4
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$2
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3
Mar-15-22	Downgrade	Mizuho	Buy → Neutral	$35 → $8
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform

Show Previous Ratings

Feb-02-26 10:02PM	Nektar Therapeutics (NKTR): A Bull Case Theory (Insider Monkey)
Jan-30-26 04:10PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.96%
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
Jan-07-26 08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-05-26 05:05PM	Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead (Motley Fool)
02:33AM	Loading…
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-21-25 07:31AM	Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) (Insider Monkey)
Dec-16-25 07:30AM	REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata (PR Newswire) -7.77%
06:24AM	Nektar sees silver lining as autoimmune drug narrowly misses in alopecia study (BioPharma Dive)
Dec-15-25 06:00PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 (PR Newswire)
Dec-08-25 12:00PM	Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy (Zacks)
Dec-05-25 06:00PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-01-25 09:55AM	Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade (Zacks) -6.29%
Nov-26-25 09:43AM	Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls (The Fly) +8.85%
07:02AM	Loading…
Nov-23-25 07:02AM	Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now? (Insider Monkey)
Nov-20-25 06:57AM	Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. (Motley Fool) -8.68%
Nov-13-25 09:55AM	Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect? (Zacks) -6.45%
Nov-08-25 05:45PM	New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Nov-07-25 10:11AM	Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
12:07AM	Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Nov-06-25 05:55PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:06PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 10:00AM	Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) -7.72%
Oct-30-25 06:00PM	Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (PR Newswire) +5.32%
10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 06:00PM	Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
09:55AM	Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High? (Zacks)
Oct-26-25 06:06AM	Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation (Insider Monkey)
08:00AM	Loading…
Oct-22-25 08:00AM	Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Oct-13-25 08:37AM	This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street (Motley Fool) +5.63%
Oct-05-25 08:41AM	Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September (Motley Fool)
Sep-25-25 05:22AM	Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock? (Zacks) -7.81%
Sep-21-25 06:43PM	These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? (Motley Fool)
Sep-18-25 05:34PM	Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today (Motley Fool) +15.06% -6.16%
12:23PM	EADV 25: Nektar presents data from AD candidate that sent stocks flying (Clinical Trials Arena)
08:45AM	Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 (PR Newswire)
Sep-09-25 07:00AM	Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 (PR Newswire) +9.56%
Sep-08-25 11:27AM	NKTR Shares Surge 38.2% in a Week: Here's What You Should Know (Zacks) +10.33%
Sep-05-25 01:32PM	Why Nektar Therapeutics Rippled Higher This Week (Motley Fool) +11.67%
Sep-03-25 07:00PM	Nektar Therapeutics to Participate in Two Investor Conferences in September (PR Newswire) +26.02%
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-08-25 06:15PM	Why Nektar Therapeutics Stock Popped 6% on Friday (Motley Fool) +6.02%
11:45AM	Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y (Zacks)
Aug-07-25 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:33PM	Nektar: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-05-25 06:10PM	Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-04-25 11:55AM	Nektar Gears Up to Report Q2 Earnings: What's in the Cards? (Zacks)
10:00AM	Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-31-25 06:00PM	Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets (PR Newswire) +5.90%
Jul-29-25 09:00AM	Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata (PR Newswire)
01:31AM	Nektar Therapeutics (NKTR) Announced Positive results for Rezpegaldesleukin (Insider Monkey)
Jul-21-25 11:02AM	3 Bullish Biotech Stocks With Explosive Growth Trends (MarketBeat)
Jul-06-25 04:01AM	Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin (Insider Monkey)
Jul-03-25 07:00PM	Why Nektar Therapeutics Stock Dived by 3% Today (Motley Fool) -5.21%
Jul-02-25 04:15PM	Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jul-01-25 07:17AM	Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire)
Jun-30-25 04:02PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
02:21PM	Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains (MarketBeat)
Jun-28-25 08:15AM	Nektar Jumps 157% on Drug Trial Data-Can It Go Even Higher? (MarketBeat)
Jun-25-25 06:45PM	Why Nektar Therapeutics Stock Was Red-Hot Today (Motley Fool) +19.10%
12:20PM	Wainwright sets over $100 target for Nektar on paradigm-shifting data (TipRanks)
11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 04:23PM	Nektar Therapeutics Launches After Unearthing 'A New Biology' In Eczema Treatment (Investor's Business Daily) +156.29%
10:54AM	Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results (Investopedia)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
09:07AM	Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam (Investor's Business Daily)
07:30AM	REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Jun-23-25 04:30PM	Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 (PR Newswire) +12.10%
May-13-25 05:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference (PR Newswire)
May-09-25 02:29PM	Q1 2025 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
09:08AM	Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down (Zacks)
03:46AM	Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... (GuruFocus.com)
May-08-25 06:25PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:19PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2025 Financial Results (PR Newswire)
May-07-25 05:20PM	Nektar Therapeutics Q1 2025 Earnings Preview (Seeking Alpha) -5.67%
May-01-25 06:00PM	Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-11-25 02:29PM	Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 (GuruFocus.com) +23.76%
11:30AM	Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? (Zacks)
Mar-22-25 06:57PM	Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil (Insider Monkey)
Mar-20-25 06:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
Mar-14-25 07:33AM	Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised) (Zacks) +9.98%
Mar-13-25 12:06PM	Q4 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
Mar-12-25 08:30PM	Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
07:00PM	Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates (Zacks)
06:12PM	Nektar: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-05-25 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
Feb-27-25 10:59AM	Nektar completes enrolment in trial of rezpegaldesleukin for alopecia areata (Clinical Trials Arena)
Feb-26-25 07:00AM	Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata (PR Newswire) -10.38%
Feb-24-25 07:00AM	Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th (PR Newswire) -9.35%
07:00AM	Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus (PR Newswire)
Feb-10-25 07:00AM	Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Feb-07-25 09:35AM	Down -38.51% in 4 Weeks, Here's Why Nektar (NKTR) Looks Ripe for a Turnaround (Zacks)
Jan-31-25 09:55AM	Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zalevsky Jonathan	Chief R&D Officer	Jan 20 '26	Sale	35.67	3,867	137,936	21,354	Jan 22 07:31 PM
Zalevsky Jonathan	Officer	Jan 20 '26	Proposed Sale	35.67	3,867	137,946		Jan 20 04:21 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 25 '25	Sale	54.28	1,157	62,802	18,971	Nov 25 08:30 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 25 '25	Sale	54.28	630	34,196	21,585	Nov 25 08:29 PM
ROBIN HOWARD W	President & CEO	Nov 25 '25	Sale	54.28	2,207	119,796	54,245	Nov 25 08:28 PM
ROBIN HOWARD W	Officer	Nov 25 '25	Proposed Sale	58.82	2,207	129,812		Nov 25 03:35 PM
Wilson Mark Andrew	Officer	Nov 25 '25	Proposed Sale	58.82	630	37,056		Nov 25 03:32 PM
Zalevsky Jonathan	Officer	Nov 25 '25	Proposed Sale	58.82	1,157	68,053		Nov 25 03:28 PM
ROBIN HOWARD W	President & CEO	Sep 09 '25	Sale	46.69	6,666	311,214	49,342	Sep 11 09:01 PM
ROBIN HOWARD W	Officer	Sep 09 '25	Proposed Sale	46.69	6,666	311,205		Sep 09 04:57 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 04 '25	Sale	33.52	1,721	57,693	17,462	Sep 08 08:32 PM
ROBIN HOWARD W	President & CEO	Sep 05 '25	Sale	38.53	6,666	256,851	56,008	Sep 08 08:31 PM
ROBIN HOWARD W	President & CEO	Sep 04 '25	Sale	33.70	5,166	174,108	62,674	Sep 08 08:31 PM
ROBIN HOWARD W	Officer	Sep 05 '25	Proposed Sale	38.53	6,666	256,838		Sep 05 04:37 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 02 '25	Sale	30.10	485	14,598	19,183	Sep 04 09:02 PM
ROBIN HOWARD W	President & CEO	Sep 02 '25	Sale	30.16	1,500	45,240	67,840	Sep 04 09:01 PM
ROBIN HOWARD W	Officer	Sep 04 '25	Proposed Sale	33.70	5,166	174,119		Sep 04 05:06 PM
Zalevsky Jonathan	Officer	Sep 04 '25	Proposed Sale	33.52	1,721	57,688		Sep 04 04:19 PM
Zalevsky Jonathan	Officer	Sep 02 '25	Proposed Sale	30.10	485	14,600		Sep 02 04:45 PM
ROBIN HOWARD W	Officer	Sep 02 '25	Proposed Sale	30.16	1,500	45,244		Sep 02 04:42 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 19 '25	Sale	26.59	725	19,278	19,668	Aug 21 09:05 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 19 '25	Sale	26.59	676	17,975	20,312	Aug 21 09:04 PM
ROBIN HOWARD W	President & CEO	Aug 19 '25	Sale	26.59	1,573	41,826	69,340	Aug 21 09:03 PM
ROBIN HOWARD W	Officer	Aug 19 '25	Proposed Sale	26.59	1,573	41,826		Aug 19 03:24 PM
Wilson Mark Andrew	Officer	Aug 19 '25	Proposed Sale	26.59	676	17,975		Aug 19 03:24 PM
Zalevsky Jonathan	Officer	Aug 19 '25	Proposed Sale	26.59	725	19,278		Aug 19 03:20 PM
Zalevsky Jonathan	Chief R&D Officer	May 19 '25	Sale	0.67	10,712	7,177	305,892	May 21 08:08 PM
Wilson Mark Andrew	Chief Legal Officer	May 19 '25	Sale	0.67	9,996	6,697	314,296	May 21 08:07 PM
ROBIN HOWARD W	President & CEO	May 19 '25	Sale	0.67	23,208	15,549	1,063,693	May 21 08:07 PM
Zalevsky Jonathan	Officer	May 19 '25	Proposed Sale	0.67	10,712	7,191		May 19 03:49 PM
Wilson Mark Andrew	Officer	May 19 '25	Proposed Sale	0.67	9,996	6,710		May 19 03:44 PM
ROBIN HOWARD W	Officer	May 19 '25	Proposed Sale	0.67	23,208	15,580		May 19 03:40 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 19 '25	Sale	1.01	10,300	10,403	316,604	Feb 21 06:07 PM
Wilson Mark Andrew	Chief Legal Officer	Feb 19 '25	Sale	1.01	11,040	11,150	324,292	Feb 21 06:06 PM
ROBIN HOWARD W	President & CEO	Feb 19 '25	Sale	1.01	23,774	24,012	1,086,901	Feb 21 06:04 PM
Wilson Mark Andrew	Officer	Feb 19 '25	Proposed Sale	1.01	11,040	11,137		Feb 19 03:27 PM
ROBIN HOWARD W	Officer	Feb 19 '25	Proposed Sale	1.01	23,774	23,983		Feb 19 03:21 PM
Zalevsky Jonathan	Officer	Feb 19 '25	Proposed Sale	1.01	10,300	10,391		Feb 19 03:18 PM

Open in Screener

TWST

Twist Bioscience Corp

Feb 06 • 04:00PM ET

49.24

+2.14 4.54 %

Healthcare • Diagnostics & Research • USA • NASD

TWST Twist Bioscience Corp daily Stock Chart

Peers: ILMN PACB CRSP EDIT NTLA BEAM SGMO AMGN REGN BIIB

| Held by: ARKK ARKG XBI IWM VTI VB IWO VBK VXF IBB

Index	RUT	P/E	-	EPS (ttm)	-1.27	Insider Own	4.53%	Shs Outstand	61.27M	Perf Week	19.89%
Market Cap	3.02B	Forward P/E	-	EPS next Y	-1.20	Insider Trans	-8.17%	Shs Float	58.53M	Perf Month	34.72%
Enterprise Value	2.92B	PEG	-	EPS next Q	-0.48	Inst Own	120.42%	Short Float	21.36%	Perf Quarter	56.22%
Income	-76.58M	P/S	7.71	EPS this Y	-38.63%	Inst Trans	0.49%	Short Ratio	8.38	Perf Half Y	96.96%
Sales	391.56M	P/B	6.62	EPS next Y	33.67%	ROA	-12.29%	Short Interest	12.50M	Perf YTD	55.23%
Book/sh	7.44	P/C	15.25	EPS next 5Y	23.15%	ROE	-16.79%	52W High	54.74 -10.05%	Perf Year	-8.24%
Cash/sh	3.23	P/FCF	-	EPS past 3/5Y	31.51% 18.31%	ROIC	-14.13%	52W Low	23.30 111.33%	Perf 3Y	69.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	22.76% 33.11%	Gross Margin	51.62%	Volatility	7.70% 6.24%	Perf 5Y	-72.69%
Dividend TTM	-	EV/Sales	7.46	EPS Y/Y TTM	62.54%	Oper. Margin	-34.35%	ATR (14)	2.60	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.37	Sales Y/Y TTM	18.59%	Profit Margin	-19.56%	RSI (14)	72.60	Recom	1.55
Dividend Gr. 3/5Y	- -	Current Ratio	3.78	EPS Q/Q	6.46%	SMA20	14.91%	Beta	2.21	Target Price	52.22
Payout	-	Debt/Eq	0.21	Sales Q/Q	16.89%	SMA50	34.30%	Rel Volume	1.38	Prev Close	47.10
Employees	979	LT Debt/Eq	0.19	Earnings	Feb 02 BMO	SMA200	50.48%	Avg Volume	1.49M	Price	49.24
IPO	Oct 31, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.92% 1.78%	Trades		Volume	2,064,825	Change	4.54%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-25	Initiated	Stephens	Overweight	$41
Dec-13-24	Initiated	Wolfe Research	Outperform	$60
Jun-04-24	Initiated	Guggenheim	Buy	$53
Jan-17-24	Upgrade	Goldman	Neutral → Buy	$25 → $45
Sep-27-23	Initiated	Berenberg	Buy	$27
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-03-23	Upgrade	Evercore ISI	In-line → Outperform	$28 → $36
Mar-02-22	Resumed	Cowen	Outperform
Oct-15-21	Resumed	Cowen	Outperform
Jun-29-21	Initiated	William Blair	Outperform
Jun-04-21	Initiated	Goldman	Neutral	$110
Apr-12-21	Initiated	Piper Sandler	Overweight	$150
Feb-05-21	Downgrade	JP Morgan	Neutral → Underweight	$100
Jan-04-21	Downgrade	Evercore ISI	Outperform → In-line
Oct-20-20	Initiated	SVB Leerink	Mkt Perform	$90
May-31-19	Initiated	Evercore ISI	Outperform
Nov-26-18	Initiated	JP Morgan	Neutral	$27

Show Previous Ratings

Feb-03-26 08:00AM	Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Feb-02-26 10:02PM	Twist Bioscience Corporation (TWST): A Bull Case Theory (Insider Monkey) +13.98%
02:27PM	Why Is Twist Bioscience Stock Soaring Monday? (Benzinga)
02:00PM	Twist Bioscience Corp (TWST) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:52PM	Twist Bioscience Q1 Earnings Call Highlights (MarketBeat)
08:25AM	Loading…
08:25AM	Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:21AM	Twist Bioscience: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:15AM	Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results (Business Wire)
Jan-27-26 10:00AM	Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jan-26-26 10:00AM	Will Twist Bioscience (TWST) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jan-12-26 08:00AM	Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue (Business Wire) +7.70%
Dec-31-25 06:26AM	Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab (GuruFocus.com)
Dec-30-25 11:48PM	Barclays Keeps Its Overweight Rating On Twist Bioscience Corporation (TWST) (Insider Monkey)
Dec-29-25 12:51PM	TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock (GuruFocus.com)
Dec-22-25 10:20PM	New Product Launch Strengthens Bull Case for Twist?Bioscience (?TWST) (Insider Monkey) +7.84%
08:00AM	Loading…
Dec-18-25 08:00AM	Twist Bioscience to Present at J.P. Morgan 2026 Healthcare Conference (Business Wire)
Dec-12-25 01:15PM	Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Dec-04-25 08:00AM	Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research (Business Wire) +5.26%
Nov-18-25 09:40AM	Company News for Nov 18, 2025 (Zacks)
04:45AM	Stephens Initiates Twist Bioscience (TWST) With Overweight Rating, Sets $41 PT (Insider Monkey)
Nov-17-25 10:13AM	Is Twist Bioscience Corporation (TWST) a Compelling Risk-Regarded Opportunity? (Insider Monkey)
Nov-14-25 02:01PM	Twist Bioscience Corp (TWST) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com) -10.13%
08:25AM	Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:34AM	Twist Bioscience: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:15AM	Twist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results (Business Wire)
Nov-13-25 09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -6.18%
Nov-12-25 08:10AM	Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-06-25 05:20PM	Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-04-25 09:11AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More (24/7 Wall St.)
08:00AM	Twist Bioscience to Present at 7th Annual Wolfe Research Healthcare Conference (Business Wire)
08:00AM	Loading…
Nov-03-25 08:00AM	Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Oct-24-25 06:20AM	Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights (Business Wire) +7.16%
Oct-23-25 08:00AM	Twist Bioscience to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results on Friday, November 14, 2025 (Business Wire)
Oct-22-25 08:53AM	Multiple Headwinds Hit Twist BioScience Corp. (TWST) in Q3 (Insider Monkey) -6.98%
Oct-06-25 08:00AM	Twist Bioscience and Element Biosciences Advance Collaboration with Launch of New Trinity Freestyle Sequencing Workflow for the AVITI System (Business Wire)
Oct-02-25 02:00PM	Twist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein Design (Business Wire)
Sep-24-25 04:47AM	Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience (Zacks)
Sep-23-25 09:23AM	5 Biotech Stocks Worth Adding to Your Portfolio Now (Zacks)
Sep-18-25 11:35AM	3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025 (Zacks)
Sep-17-25 02:18PM	TD Cowen Reaffirms Buy on Twist Bioscience (TWST) Amid Scaling and Margin Gains (Insider Monkey)
Sep-03-25 08:00AM	Twist Bioscience to Present at Baird 2025 Global Healthcare Conference (Business Wire)
Sep-02-25 08:00AM	Twist Bioscience Collaborates with Synthetic Design Lab (Business Wire)
Aug-19-25 08:00AM	Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution (Business Wire)
Aug-13-25 07:30AM	[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Aug-07-25 09:35AM	After Plunging 33.8% in 4 Weeks, Here's Why the Trend Might Reverse for Twist Bioscience (TWST) (Zacks)
Aug-06-25 08:00AM	Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors (Business Wire) -5.89%
Aug-05-25 03:08AM	Twist Bioscience Corp (TWST) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com) -8.90%
Aug-04-25 08:25AM	Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -10.30%
07:24AM	Twist Bioscience: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
07:15AM	Twist Bioscience Announces Fiscal 2025 Third Quarter Financial Results (Business Wire)
Jul-31-25 08:00AM	Twist Bioscience Expands In Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse Model (Business Wire)
Jul-28-25 08:24AM	Is Twist Bioscience Corp. (TWST) Nearing Profitability? (Insider Monkey)
Jul-24-25 08:00AM	Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-14-25 08:00AM	Twist Bioscience to Report Fiscal 2025 Third Quarter Financial Results on Monday, August 4, 2025 (Business Wire)
Jul-07-25 08:00AM	Twist Bioscience Expands Express Delivery Turnaround Time to All Gene Fragments Regardless of Format (Business Wire) -6.76%
Jun-23-25 01:40AM	Twist and Element Biosciences Expands Pact for Sequencing Workflow Solutions (Insider Monkey)
May-22-25 08:00AM	Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions (Business Wire)
May-15-25 08:00AM	Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference (Business Wire)
May-13-25 08:00AM	Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
May-08-25 11:43PM	Twist Bioscience Corporation (TWST): Among Nicholas J. Pritzker's Stock Picks with Huge Upside Potential (Insider Monkey) -5.49%
08:00AM	Twist Bioscience and Ginkgo Bioworks Revise Collaboration (Business Wire)
May-06-25 03:02AM	Twist Bioscience Corp (TWST) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com) -8.85%
01:18AM	Q2 2025 Twist Bioscience Corp Earnings Call (Thomson Reuters StreetEvents)
May-05-25 11:41AM	Twist Bioscience Corporation (TWST) Q2 2025 Earnings Call Transcript (Seeking Alpha) -8.44%
08:25AM	Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:25AM	Twist Bioscience: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
07:15AM	Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results (Business Wire)
07:10AM	Twist Bioscience Spins Out DNA Data Storage as Independent Company (Business Wire)
May-02-25 09:23AM	What To Expect From Twist Bioscience Corp (TWST) Q2 2025 Earnings (GuruFocus.com)
May-01-25 02:06PM	Twist Bioscience: Experiencing Solid Growth But Significantly Overvalued (Seeking Alpha)
12:05PM	Twist Bioscience Q2 Earnings Preview: Innovative Products, Not Enough Buyers (Seeking Alpha)
Apr-24-25 08:00AM	Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System (Business Wire) +6.78%
Apr-14-25 08:00AM	Twist Bioscience to Report Fiscal 2025 Second Quarter Financial Results on Monday, May 5, 2025 (Business Wire)
Mar-31-25 09:03AM	The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics (Zacks)
08:00AM	Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics (Business Wire)
Mar-28-25 09:39AM	Promising Genomics & Synthetic Biology Stocks to Consider in 2025 (Zacks)
Mar-20-25 04:58PM	Twist Bioscience (TWST): The Worst High-Risk High-Reward Growth Stock to Buy (InsiderMonkey)
Mar-12-25 12:12PM	Twist Bioscience (TWST) Moves 6.6% Higher: Will This Strength Last? (Zacks)
Mar-11-25 07:30AM	Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost (Business Wire) +6.59%
Mar-01-25 02:38PM	Is Twist Bioscience Corporation (TWST) The Best Immunology Stock To Buy Now? (Insider Monkey)
Feb-25-25 08:00AM	Twist Bioscience to Present at Upcoming Investor Conferences (Business Wire)
Feb-19-25 08:00AM	Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Feb-06-25 04:58PM	Twist Bioscience Corporation (TWST): Among Cathie Woods Top Stock Picks for 2025 (Insider Monkey)
12:00PM	Twist Bioscience (TWST) Upgraded to Buy: Here's What You Should Know (Zacks)
Feb-04-25 02:01AM	Twist Bioscience Corp (TWST) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
12:47AM	Q1 2025 Twist Bioscience Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-03-25 08:25AM	Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:25AM	Twist Bioscience: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:15AM	Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results (Business Wire)
Jan-31-25 07:05AM	Twist Bioscience Corp (TWST) Q1 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
Jan-22-25 08:00AM	Twist Bioscience to Report Fiscal 2025 First Quarter Financial Results on Monday, February 3, 2025 (Business Wire)
Dec-27-24 12:00PM	All You Need to Know About Twist Bioscience (TWST) Rating Upgrade to Buy (Zacks)
Dec-23-24 08:48AM	Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains? (Zacks)
Dec-19-24 08:00AM	Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-16-24 09:55AM	Twist Bioscience (TWST) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Dec-11-24 11:59AM	Why Twist Bioscience (TWST) Is the Worst ARK Stock to Buy According to Short Sellers (Insider Monkey) -5.24%
Nov-27-24 07:30AM	Twist Bioscience named a Best Idea for 2025 at TD Cowen (TipRanks)
Nov-20-24 09:15AM	AI's Growing Role in Transforming Healthcare Delivers Innovations in Diagnostics, Patient Care (PR Newswire)
Nov-19-24 09:15PM	Twist Bioscience price target lowered to $52 from $55 at Barclays (TipRanks)
06:49PM	Twist Bioscience Corporation (TWST): Among the Best Genomics Stocks to Buy Right Now (Insider Monkey)

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JOHANNESSEN JAN	Director	Feb 06 '26	Proposed Sale	47.91	2,200	105,395		Feb 06 03:16 PM
Finn Patrick John	President and COO	Feb 03 '26	Sale	46.58	2,705	125,988	307,788	Feb 05 04:05 PM
Cho Dennis	See Remarks	Feb 03 '26	Sale	46.58	1,099	51,187	143,581	Feb 05 04:05 PM
Leproust Emily M.	Chief Executive Officer	Feb 03 '26	Sale	46.58	5,001	232,927	869,312	Feb 05 04:05 PM
WERNER ROBERT F.	Chief Accounting Officer	Feb 04 '26	Sale	45.65	7,000	319,536	58,738	Feb 05 04:05 PM
WERNER ROBERT F.	Chief Accounting Officer	Feb 03 '26	Sale	46.58	175	8,151	65,738	Feb 05 04:05 PM
Green Paula	SVP of Human Resources	Feb 03 '26	Sale	46.58	1,194	55,612	165,445	Feb 05 04:05 PM
WERNER ROBERT F.	Officer	Feb 04 '26	Proposed Sale	45.65	7,000	319,533		Feb 04 02:29 PM
Finn Patrick John	Officer	Feb 03 '26	Proposed Sale	46.58	2,705	125,987		Feb 03 03:44 PM
WERNER ROBERT F.	Officer	Feb 03 '26	Proposed Sale	46.58	175	8,151		Feb 03 03:26 PM
Green Paula	Officer	Feb 03 '26	Proposed Sale	46.58	1,194	55,611		Feb 03 03:23 PM
Cho Dennis	Officer	Feb 03 '26	Proposed Sale	46.58	1,099	51,186		Feb 03 03:20 PM
Leproust Emily M.	Officer	Feb 03 '26	Proposed Sale	46.58	5,001	232,924		Feb 03 03:19 PM
Finn Patrick John	President and COO	Jan 23 '26	Sale	44.91	2,390	107,330	310,493	Jan 27 04:05 PM
Finn Patrick John	Officer	Jan 23 '26	Proposed Sale	44.91	2,390	107,329		Jan 23 03:17 PM
Laponis Adam	Chief Financial Officer	Jan 13 '26	Sale	40.00	3,000	120,000	137,031	Jan 15 04:13 PM
Finn Patrick John	President and COO	Jan 13 '26	Option Exercise	8.82	3,279	28,921	336,162	Jan 15 04:13 PM
Finn Patrick John	President and COO	Jan 13 '26	Sale	40.00	23,279	931,160	312,883	Jan 15 04:13 PM
Laponis Adam	Chief Financial Officer	Jan 09 '26	Sale	35.26	2,738	96,545	140,031	Jan 13 04:05 PM
Finn Patrick John	Officer	Jan 13 '26	Proposed Sale	40.00	23,279	931,160		Jan 13 02:46 PM
Laponis Adam	Officer	Jan 13 '26	Proposed Sale	40.00	3,000	120,000		Jan 13 02:42 PM
Laponis Adam	Officer	Jan 09 '26	Proposed Sale	35.26	2,738	96,544		Jan 09 03:12 PM
Green Paula	SVP of Human Resources	Dec 22 '25	Sale	34.56	273	9,434	166,639	Dec 23 04:05 PM
Cho Dennis	See Remarks	Dec 22 '25	Sale	34.56	324	11,196	144,680	Dec 23 04:05 PM
Leproust Emily M.	Chief Executive Officer	Dec 22 '25	Sale	34.56	1,605	55,462	874,313	Dec 23 04:05 PM
Cho Dennis	Officer	Dec 22 '25	Proposed Sale	34.56	324	11,196		Dec 22 03:22 PM
Green Paula	Officer	Dec 22 '25	Proposed Sale	34.56	273	9,434		Dec 22 03:16 PM
Leproust Emily M.	Officer	Dec 22 '25	Proposed Sale	34.56	1,605	55,462		Dec 22 03:11 PM
Cho Dennis	See Remarks	Dec 08 '25	Sale	32.88	398	13,085	145,004	Dec 10 04:05 PM
Leproust Emily M.	Chief Executive Officer	Dec 08 '25	Sale	32.88	2,255	74,140	875,918	Dec 10 04:05 PM
Green Paula	SVP of Human Resources	Dec 08 '25	Sale	32.88	877	28,834	166,912	Dec 10 04:05 PM
WERNER ROBERT F.	Chief Accounting Officer	Dec 08 '25	Sale	32.88	230	7,562	65,913	Dec 10 04:05 PM
Leproust Emily M.	Officer	Dec 08 '25	Proposed Sale	32.88	2,255	74,139		Dec 08 03:33 PM
Cho Dennis	Officer	Dec 08 '25	Proposed Sale	32.88	398	13,085		Dec 08 03:31 PM
Green Paula	Officer	Dec 08 '25	Proposed Sale	32.88	877	28,834		Dec 08 03:22 PM
WERNER ROBERT F.	Officer	Dec 08 '25	Proposed Sale	32.88	230	7,562		Dec 08 03:20 PM
Cho Dennis	See Remarks	Nov 21 '25	Sale	26.50	757	20,063	145,402	Nov 25 04:05 PM
Finn Patrick John	President and COO	Nov 21 '25	Sale	26.50	1,776	47,070	332,883	Nov 25 04:05 PM
Green Paula	SVP of Human Resources	Nov 21 '25	Sale	26.50	598	15,849	167,789	Nov 25 04:05 PM
Laponis Adam	Chief Financial Officer	Nov 21 '25	Sale	26.50	887	23,509	142,769	Nov 25 04:05 PM
Leproust Emily M.	Chief Executive Officer	Nov 21 '25	Sale	26.50	2,663	70,579	878,173	Nov 25 04:05 PM
WERNER ROBERT F.	Chief Accounting Officer	Nov 24 '25	Sale	28.71	822	23,599	66,143	Nov 25 04:05 PM
WERNER ROBERT F.	Chief Accounting Officer	Nov 21 '25	Sale	26.50	229	6,069	66,965	Nov 25 04:05 PM
WERNER ROBERT F.	Officer	Nov 24 '25	Proposed Sale	28.71	822	23,599		Nov 24 03:12 PM
WERNER ROBERT F.	Officer	Nov 21 '25	Proposed Sale	26.50	229	6,069		Nov 21 03:36 PM
Leproust Emily M.	Officer	Nov 21 '25	Proposed Sale	26.50	2,663	70,579		Nov 21 03:30 PM
Laponis Adam	Officer	Nov 21 '25	Proposed Sale	26.50	887	23,509		Nov 21 03:24 PM
Green Paula	Officer	Nov 21 '25	Proposed Sale	26.50	598	15,849		Nov 21 03:19 PM
Finn Patrick John	Officer	Nov 21 '25	Proposed Sale	26.50	1,776	47,070		Nov 21 03:18 PM
Cho Dennis	Officer	Nov 21 '25	Proposed Sale	26.50	757	20,063		Nov 21 03:14 PM
JOHANNESSEN JAN	Director	Nov 18 '25	Sale	24.77	7,044	174,480	14,859	Nov 20 04:05 PM
JOHANNESSEN JAN	Director	Nov 18 '25	Proposed Sale	24.77	7,044	174,480		Nov 18 11:54 AM
Cho Dennis	See Remarks	Nov 03 '25	Sale	32.08	1,019	32,689	120,694	Nov 05 04:05 PM
Finn Patrick John	President and COO	Nov 03 '25	Sale	32.08	2,755	88,379	265,919	Nov 05 04:05 PM
Green Paula	SVP of Human Resources	Nov 03 '25	Sale	32.08	1,084	34,774	142,187	Nov 05 04:05 PM
Leproust Emily M.	Chief Executive Officer	Nov 03 '25	Sale	32.08	4,887	156,772	733,922	Nov 05 04:05 PM
WERNER ROBERT F.	Chief Accounting Officer	Nov 03 '25	Sale	32.08	160	5,133	50,870	Nov 05 04:05 PM
Cho Dennis	See Remarks	Oct 30 '25	Sale	31.44	6,515	204,860	121,713	Nov 03 04:05 PM
Finn Patrick John	President and COO	Oct 30 '25	Sale	31.44	17,606	553,608	268,674	Nov 03 04:05 PM
Green Paula	SVP of Human Resources	Oct 30 '25	Sale	31.44	6,920	217,595	143,271	Nov 03 04:05 PM
Leproust Emily M.	Chief Executive Officer	Oct 30 '25	Sale	31.44	31,379	986,691	738,809	Nov 03 04:05 PM
Laponis Adam	Chief Financial Officer	Oct 30 '25	Sale	31.44	5,517	173,478	111,008	Nov 03 04:05 PM
WERNER ROBERT F.	Chief Accounting Officer	Oct 30 '25	Sale	31.44	1,016	31,947	51,030	Nov 03 04:05 PM
WERNER ROBERT F.	Officer	Nov 03 '25	Proposed Sale	32.08	160	5,133		Nov 03 03:23 PM
Green Paula	Officer	Nov 03 '25	Proposed Sale	32.08	1,084	34,774		Nov 03 03:21 PM
Finn Patrick John	Officer	Nov 03 '25	Proposed Sale	32.08	2,755	88,379		Nov 03 03:19 PM
Leproust Emily M.	Officer	Nov 03 '25	Proposed Sale	32.08	4,887	156,772		Nov 03 03:18 PM
Cho Dennis	Officer	Nov 03 '25	Proposed Sale	32.08	1,019	32,689		Nov 03 03:12 PM
WERNER ROBERT F.	Officer	Oct 30 '25	Proposed Sale	31.44	1,016	31,947		Oct 30 04:00 PM
Cho Dennis	Officer	Oct 30 '25	Proposed Sale	31.44	6,515	204,860		Oct 30 03:52 PM
Leproust Emily M.	Officer	Oct 30 '25	Proposed Sale	31.44	31,379	986,691		Oct 30 03:50 PM
Finn Patrick John	Officer	Oct 30 '25	Proposed Sale	31.44	17,606	553,608		Oct 30 03:46 PM
Green Paula	Officer	Oct 30 '25	Proposed Sale	31.44	6,920	217,595		Oct 30 03:46 PM
Laponis Adam	Officer	Oct 30 '25	Proposed Sale	31.44	5,517	173,478		Oct 30 03:43 PM
Finn Patrick John	President and COO	Oct 23 '25	Sale	30.88	2,240	69,160	206,495	Oct 27 04:05 PM
Finn Patrick John	Officer	Oct 23 '25	Proposed Sale	30.87	2,240	69,160		Oct 23 03:13 PM
Laponis Adam	Chief Financial Officer	Oct 08 '25	Sale	31.15	3,000	93,450	94,042	Oct 10 04:05 PM
Laponis Adam	Chief Financial Officer	Oct 09 '25	Sale	32.92	2,517	82,865	91,525	Oct 10 04:05 PM
Laponis Adam	Officer	Oct 09 '25	Proposed Sale	32.92	2,517	82,864		Oct 09 03:13 PM
Laponis Adam	Chief Financial Officer	Oct 06 '25	Sale	32.19	5,875	189,099	97,042	Oct 08 04:05 PM
Leproust Emily M.	Chief Executive Officer	Oct 06 '25	Sale	32.19	31,348	1,008,998	601,212	Oct 08 04:05 PM
WERNER ROBERT F.	Chief Accounting Officer	Oct 06 '25	Sale	32.19	2,041	65,694	46,413	Oct 08 04:05 PM
Green Paula	SVP of Human Resources	Oct 06 '25	Sale	32.19	9,724	312,986	114,678	Oct 08 04:05 PM
Finn Patrick John	President and COO	Oct 06 '25	Sale	32.19	23,747	764,345	208,735	Oct 08 04:05 PM
Cho Dennis	See Remarks	Oct 06 '25	Sale	32.19	3,876	124,757	98,710	Oct 08 04:05 PM
Laponis Adam	Officer	Oct 08 '25	Proposed Sale	31.15	3,000	93,450		Oct 08 09:50 AM
Laponis Adam	Officer	Oct 06 '25	Proposed Sale	32.19	5,875	189,099		Oct 06 05:18 PM
Leproust Emily M.	Officer	Oct 06 '25	Proposed Sale	32.19	31,348	1,008,998		Oct 06 05:15 PM
WERNER ROBERT F.	Officer	Oct 06 '25	Proposed Sale	32.19	2,041	65,694		Oct 06 05:09 PM
Finn Patrick John	Officer	Oct 06 '25	Proposed Sale	32.19	23,747	764,345		Oct 06 04:52 PM
Green Paula	Officer	Oct 06 '25	Proposed Sale	32.19	9,724	312,986		Oct 06 04:41 PM
Cho Dennis	Officer	Oct 06 '25	Proposed Sale	32.19	3,876	124,757		Oct 06 04:41 PM
Cho Dennis	See Remarks	Oct 02 '25	Sale	29.16	124	3,616	102,586	Oct 06 04:05 PM
Green Paula	SVP of Human Resources	Oct 02 '25	Sale	29.16	140	4,083	124,402	Oct 06 04:05 PM
Leproust Emily M.	Chief Executive Officer	Oct 02 '25	Sale	29.16	476	13,881	632,560	Oct 06 04:05 PM
Finn Patrick John	President and COO	Oct 02 '25	Sale	29.16	206	6,007	232,482	Oct 06 04:05 PM
Green Paula	Officer	Oct 02 '25	Proposed Sale	29.16	140	4,083		Oct 02 04:33 PM
Cho Dennis	Officer	Oct 02 '25	Proposed Sale	29.16	124	3,616		Oct 02 03:49 PM
Finn Patrick John	Officer	Oct 02 '25	Proposed Sale	29.16	206	6,007		Oct 02 03:35 PM
Leproust Emily M.	Officer	Oct 02 '25	Proposed Sale	29.16	476	13,881		Oct 02 03:21 PM

NKTR

Nektar Therapeutics

TWST

Twist Bioscience Corp

Upgrade your FINVIZ experience